Follicular lymphoma outcomes after frontline chemoimmunotherapy
| Regimen . | ORR . | PFS . | OS . | % Relapsing within 2 years . | Transformation . |
|---|---|---|---|---|---|
| R-CHOP/R-CVP/R-FCM followed by O vs M8 | 100% | 51% (M) vs 35% (O) at 10 y | 80.1% (M) vs 79.9% (O) at 10 y | ≈20%-25% | 40 patients |
| R-CHOP/CHOP plus 131I-tositumomab52 | 99%/98% | 42%/56% at 10 y | 81%/75% at 10 y | Not formally evaluated. Estimate 22%/20% based on PFS curves | N/A |
| BR3 | 97% | ≈74% at 5 y* | ≈84% at 5 y* | ≈20% | N/A |
| BR5,6 | 93.8% | Median 69.5 mo at 48-mo follow-up | 71% at 10 y | ≈20% | N/A |
| O-chemo4 | 88.5% | 80% at 3 y | N/A | 9.4% | 13 patients |
| R27 | 84% | 77% at 3 y | 94% at 3 y | 16% | 10/49 patients |
| O-Len27 | 94% | 82% at 3 y | N/A | 14% | 3/10 biopsied patients |
| Regimen . | ORR . | PFS . | OS . | % Relapsing within 2 years . | Transformation . |
|---|---|---|---|---|---|
| R-CHOP/R-CVP/R-FCM followed by O vs M8 | 100% | 51% (M) vs 35% (O) at 10 y | 80.1% (M) vs 79.9% (O) at 10 y | ≈20%-25% | 40 patients |
| R-CHOP/CHOP plus 131I-tositumomab52 | 99%/98% | 42%/56% at 10 y | 81%/75% at 10 y | Not formally evaluated. Estimate 22%/20% based on PFS curves | N/A |
| BR3 | 97% | ≈74% at 5 y* | ≈84% at 5 y* | ≈20% | N/A |
| BR5,6 | 93.8% | Median 69.5 mo at 48-mo follow-up | 71% at 10 y | ≈20% | N/A |
| O-chemo4 | 88.5% | 80% at 3 y | N/A | 9.4% | 13 patients |
| R27 | 84% | 77% at 3 y | 94% at 3 y | 16% | 10/49 patients |
| O-Len27 | 94% | 82% at 3 y | N/A | 14% | 3/10 biopsied patients |
Indolent non-Hodgkin lymphoma.
G/R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone; Len, lenalidomide; M, maintenance; N/A, not available; O, observation.